1. Home
  2. SLE vs APLM Comparison

SLE vs APLM Comparison

Compare SLE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLE
  • APLM
  • Stock Information
  • Founded
  • SLE 2014
  • APLM 2016
  • Country
  • SLE United States
  • APLM United States
  • Employees
  • SLE N/A
  • APLM N/A
  • Industry
  • SLE Services-Misc. Amusement & Recreation
  • APLM Blank Checks
  • Sector
  • SLE Consumer Discretionary
  • APLM Finance
  • Exchange
  • SLE Nasdaq
  • APLM Nasdaq
  • Market Cap
  • SLE 6.5M
  • APLM 6.9M
  • IPO Year
  • SLE 2019
  • APLM N/A
  • Fundamental
  • Price
  • SLE $0.13
  • APLM $6.50
  • Analyst Decision
  • SLE Strong Buy
  • APLM
  • Analyst Count
  • SLE 2
  • APLM 0
  • Target Price
  • SLE $2.50
  • APLM N/A
  • AVG Volume (30 Days)
  • SLE 14.5M
  • APLM 9.8K
  • Earning Date
  • SLE 05-15-2025
  • APLM 04-03-2025
  • Dividend Yield
  • SLE N/A
  • APLM N/A
  • EPS Growth
  • SLE N/A
  • APLM N/A
  • EPS
  • SLE N/A
  • APLM N/A
  • Revenue
  • SLE $14,691,000.00
  • APLM $198,000.00
  • Revenue This Year
  • SLE N/A
  • APLM $415.15
  • Revenue Next Year
  • SLE $30.36
  • APLM N/A
  • P/E Ratio
  • SLE N/A
  • APLM N/A
  • Revenue Growth
  • SLE N/A
  • APLM N/A
  • 52 Week Low
  • SLE $0.12
  • APLM $4.47
  • 52 Week High
  • SLE $1.64
  • APLM $35.98
  • Technical
  • Relative Strength Index (RSI)
  • SLE 37.97
  • APLM 53.81
  • Support Level
  • SLE $0.12
  • APLM $5.96
  • Resistance Level
  • SLE $0.29
  • APLM $7.39
  • Average True Range (ATR)
  • SLE 0.04
  • APLM 0.77
  • MACD
  • SLE -0.00
  • APLM 0.08
  • Stochastic Oscillator
  • SLE 5.39
  • APLM 54.43

About SLE Super League Enterprise Inc.

Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: